Gilead goes after an HIV cure; Veloxis wins orphan status;

@FierceBiotech: Hunting a fast approval in lung cancer, Roche racks up a positive PhII for 'atezo.' Article | Follow @FierceBiotech

@JohnCFierce: Heard the latest Kite rumor? CEO says it ain't so. More | Follow @JohnCFierce

> Now that Gilead ($GILD) has cured hep C--with rivals looking to compete on market share--Bloomberg reviews the big biotech's next-gen work on HIV, including a potential cure dubbed GS-9620 that employs a "kick and kill" approach to uprooting and extinguishing the virus. Story

> Denmark's Veloxis Pharmaceuticals (OMX: VELO) announced that the FDA granted EnvarsusXR orphan drug status for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Release

Medical Device News

@FierceMedDev: Myriad snags Medicare coverage for prostate cancer test. News from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Bad news in California: Boston Sci to close to two facilities, Abbott cuts 160+ employees. Report | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: NOWDiagnostics gets FDA blessing for one-step pregnancy test. Story | Follow @EmilyWFierce

> GE gets FDA nod for low-dose computer CT lung cancer screening device. Story

> FDA: International regs don't protect patients from contaminated intraocular lenses. Article

Pharma News

@FiercePharma: ICYMI from FiercePharmaAsia: GeneWeave fits China antibiotic resistance fight, Decheng says. More | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sun U.S. sales gut-kicked by supply constraints as it works on FDA concerns at Halol plant. Story | Follow @EricPFierce

@CarlyHFierce: Probing lawmakers grill Valeant on price hikes. FiercePharma article | Follow @CarlyHFierce

> India, EU scramble to resolve drug ban so trade talks don't go down the drain. Story

> Stalwart brands from AZ, Glaxo and Sanofi top ranks of most-prescribed meds. Article

Animal Health News

> ImmuCell Q2 sales up, but not at levels reached earlier in the year. Item

> Merck debuts Fortegra in South America to combat coccidiosis in broilers. Story

> Frozen raw cat food recall by Northwest Farm Food Coop. More

> Parnell Pharmaceuticals says first-half losses narrow as it gears up pipeline. Report

> In wake of bird flu, Minnesota turkey producers slowly restocking flocks. Article

Biotech IT News

> Soon-Shiong allies with PA biomedical centers to further genomic research. News

> FDA adds alerts to Android drug shortages app. Item

> Google hooks up with DexCom to apply miniaturized electronics to diabetes monitoring. Story

> Trader accused of using hacked newswires to make $2.3M from Dendreon implosion. Article

> BioClinica makes eClinical suite available through a range of cloud options. Report

Pharma Marketing News

> FDA approves Purdue's controversial OxyContin for kids aged 11 to 16. Item

> Mylan hopes Disney can add new magic to its allergy-fighting kingdom. Report

> BMS revives Orencia DTC advertising after two-year absence. Story

> Has Kim Kardashian ruined pharma marketing, too? Fallout from the infamous Instagram post. More

> Sanofi adds its sales heft to Relypsa's forthcoming patiromer launch. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.